DEPARTMENT
OF RESEARCH, MONILEK HOSPITAL AND RESEARCH CENTER, JAWAHAR
NAGAR, JAIPUR.
ONGOING EPIDEMIOLOGICAL RESEARCH PROJECTS |
Study |
Focus |
Sponsor |
Current
Status |
PURE (Prospective
urban rural epidemiology study) |
15 years
prospective study of risk factors and outcomes in cardiovascular
diseases in urban and rural population in 15 locations
in India and 15 countries worldwide (n=150,000). |
St John Medical
College Bangalore; and Mc Master University, Hamilton,
Canada. |
Target =
5000.
Urban =2500
Rural = 2500
|
DST-Women’s
Health study |
Study of
risk factors for chronic diseases in middle aged women
and effect of educational interventions at 8 locations
in India (n = 10,000) |
All India
Institute of Medical Sciences, New Delhi; and Department
of Science and Technology, Government of India. |
Target =
1000
Urban = 500
Rural = 500
Intervention started.
|
India Heart
Watch and Jaipur Heart Watch –5 |
Study of
cardiovascular risk factors among adults in >20 Indian
urban locations in every Indian state (n=10,000) |
Monilek Hospital
and Research Centre, Jaipur and South Asian Society
of atherosclerosis and Thrombosis, Bangalore and Minneapolis,
USA. |
Recruitment
=1775 |
WDF- MARG
study |
Study of
knowledge and awareness regarding obesity and diabetes
among school children in 3 locations in India and effect
of nutritional education intervention (n=25000) |
World Diabetes
Federation, Copenhagen, Denmark; and Diabetes Foundation
of India/ Fortis Hospital, New Delhi. |
Target =
10,000
Recruitment = 4000
|
SRS-VA study
million Deaths study |
Prospective
study of causes of deaths in India and effect of life
style factors on cause of deaths (India –wide
study) |
Sample registration
survey and Registrar General of India, New Delhi; and
university of Toronto, Toronto, Canada. |
Target =
1000
Recruitment = 1000.
|
Inter Stroke |
Indian standardized
case- control study to identify conventional and emerging
risk factor associated with stroke. |
St Johns
Research Institute, Bangalore. |
Target =
30 case and control each.
Recruitment = 14 cases and 6 controls
|
MONILEK
HOSPITAL & RESEARCH CENTER, JAIPUR
DEPARTMENT OF RESEARCH ONGOING CLINICAL TRIALS |
STUDY
TITLE
|
OBJECTIVE
|
SPONSOR
|
STATUS
|
POISE STUDY
|
PERIPOERATIVE
ISCHEMIA STUDY IN HIGH RISK CARDIAC PATIENTS UNDERGOING
NON-CARDIAC SURGERY
|
ST. JOHN’S
MEDICAL COLLEGE, BANGLORE AND MCMASTER UNIVERSITY OF
CANADA
|
TARGET=50
RECRUITMENT=64
ONGOING
|
PROFESS
STUDY
|
RANDOMISED
STUDY OF CLOPIDOGREL VERSUS ASPIRIN-DIPYRAMIDOLE FOR
PREVENTION OF SECOND STROKES
|
ST JOHN’S
MEDICAL COLLEGE BANGLORE UNIVERSITY OF MUNICH GERMANY
AND MCMASTER UNIVERSITY CANADA
|
RECRUITMENT=30
FOLLOW-UP ONGOING
|
HAP STUDY
|
PHASE-3
RANDOMISED TRIAL OF TELEVANCIN VERSUS VANCOMYCIN IN
HOSPITAL ACQUIRED GRAM-POSITIVE PNEUMONIA
|
QUINTILES
INDIA LTD. MUMBAI
|
COMPLETED
SITE CLOSED OUT
5 SUBJECTS RECRUITED
|
DPP-4 EARLY
DIABETES STUDY
|
PHASE-2
EVALUATION OF A NOVEL DPP-4 INHIBITOR IN NEWLY DIAGNOSED
DIABETES
|
SIRO CLINPHARM
LTD. MUMBAI
|
COMPLETED
SITE CLOSED OUT
|
SONOMA STUDY
|
PHASE-3
STUDY OF A NOVEL ANTITHROMBOTIC DRUG IN TREATMENT OF
VENOUS CATHETER THROMBOSIS
|
QUINTILES
INDIA LTD. MUMBAI
|
COMPLETED
SITE CLOSED OUT
|
RED HEART
PILL STUDY
|
PROOF OF
EFFICACY STUDY OF COMBINATION POLYPHARMACY IN CARDIOVASCULAR
DISEASES
|
DR. REDDY’S
LAB HYDERABAD
|
25 SUBJECTS
RECRUITED VISITS COMPLETED OF ALL SUBJECTS
|
RIO- INDIA
STUDY
|
PHASE-3
STUDY OF SAFETY AND EFFICACY OF RIM0NABANT IN HIGH-RISK
OBESE SUBJECTS
|
CIPLA INDIA
LTD. MUMBAI
|
10 SUBJECTS
RECRUITED
|
POLYCAP
STUDY
|
PHASE-4
RANDOMISED TRIAL OF SAFETY AND EFFICACY OF INDIVIDUAL
COMPONENTS AND DIFFERENT COMBINATIONS OF POLYPILL IN
INDIAN SCENARIO
|
ST JOHN’S
MEDICAL COLLEGE BANGLORE AND MCMASTER UNIVERSITY CANADA
|
ONGOING
TARGET=COMPETETIVE
SCREENED=11
RECRUITED =7
|
VITATOPS
STUDY
|
HOMOCYSTEINE
LOWERING VITAMINS TO
PREVENT SECOND STROKE
|
ST. JOHN’S
MEDICAL COLLEGE BANGLORE AND UNIVERSITY OF WESTERN AUSTRALIA
PERTH AUSTRALIA
|
TARGET30 RECRUITMENT=22 FOLLOW-UP ONGOING
|
Denosumab
study
|
PHASE-3
DOUBLE BLIND PLACEBO CONTROLLED STUDY OF DENOSUMAB IN
PROLONGING BONE METASTASISIN HORMONE REFRACTORY PROSTRATE
CANCER
|
AMGEN INC CA
QUINTILES
|
ONGOING
TARGET=5
SCREENED=1
RECRUITED =0
|
